Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023
Powered by
Unlock hidden opportunities in the Pharmaceuticals industry
Global Markets Direct’s, ‘Lipid Storage Disorders (Lipidoses) – Drugs In Development, 2023’, provides an overview of the Lipid Storage Disorders (Lipidoses) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Lipid Storage Disorders (Lipidoses), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lipid Storage Disorders (Lipidoses) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note:
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase
* Global Markets Direct, is a research brand owned and operated by GlobalData.
Scope
- The report provides a snapshot of the global therapeutic landscape of Lipid Storage Disorders (Lipidoses)
- The report reviews pipeline therapeutics for Lipid Storage Disorders (Lipidoses) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lipid Storage Disorders (Lipidoses) therapeutics and enlists all their major and minor projects
- The report assesses Lipid Storage Disorders (Lipidoses) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lipid Storage Disorders (Lipidoses)
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lipid Storage Disorders (Lipidoses)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lipid Storage Disorders (Lipidoses) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Key Players
4D Molecular Therapeutics IncAceLink Therapeutics Inc
Aceragen Inc
Adienne Pharma & Biotech SA
Allievex Corp
Allife Medical Science and Technology Co Ltd
Amicus Therapeutics Inc
Apteeus SAS
Azafaros BV
Be Biopharma Inc
Belrose Pharma Inc
Bial - Portela & Ca SA
BioArctic AB
Bioasis Technologies Inc
Biosidus SA
BioStrategies LC
Bloomsbury Genetic Therapies Ltd
Blue Turtle Bio Technologies Inc
CANbridge Life Sciences Ltd
CellGenTech Inc
Centogene NV
Chameleon Biosciences Inc
Chiesi Farmaceutici SpA
Coave Therapeutics
Cyclo Therapeutics Inc
CycloLab Cyclodextrin Research and Development Laboratory Ltd
Deep Genomics Inc
Denali Therapeutics Inc
Dorphan SA
Duke University
Edenbridge Pharmaceuticals LLC
Eleva GmbH
Eli Lilly and Co
Endece LLC
Equaly SA
Erad Therapeutics Inc
Evox Therapeutics Ltd
Freeline Therapeutics Holdings Plc
Gain Therapeutics Inc
GC Biopharma Corp
Gene Therapy Research Institution Co Ltd
Generation Bio Co
Generium
Hanmi Pharmaceuticals Co Ltd
Idorsia Pharmaceutical Ltd
ILIAS Biologics Inc
Immorna Hangzhou Biotechnology Co Ltd
IntraBio Ltd
ISU ABXIS Co Ltd
Jasper Therapeutics Inc
Johnson & Johnson
Kashiv BioSciences LLC
Kumamoto University
KYORIN Pharmaceutical Co Ltd
Kyoto Prefectural University of Medicine
Liberyx Therapeutics Ltd
Lysogene SAS
M6P Therapeutics
Mandos LLC
Merck & Co Inc
MOGAM Biotechnology Research Institute
NeuImmune Inc
Northwestern University
Okklo Life Sciences BV
Oragenics Inc
Oraxion Therapeutics Inc
Oregon State University
Orphazyme A/S
Passage Bio Inc
Perlara PBC
Pfizer Inc
Pharming Group NV
Polaryx Therapeutics Inc
Prevacus Inc
Prevail Therapeutics Inc
ProfoundBio Suzhou Co Ltd
Pronacera Therapeutics SL
Recursion Pharmaceuticals Inc
Sangamo Therapeutics Inc
Sanofi
Scenic Biotech BV
Shanghai Lingyi Biotechnology Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Sichuan Zhishan Weixin Biotechnology Co Ltd
Sigilon Therapeutics Inc
SmartPharm Therapeutics Inc
SOM Biotech SL
Spanish National Research Council
StrideBio Inc
Synaptogenix Inc
Takeda Pharmaceutical Co Ltd
Taysha Gene Therapies Inc
The Hospital for Sick Children
Tokyo Medical and Dental University
U.S. National Institutes of Health
UniQure NV
Universiteit Utrecht
University Hospitals Leuven
University of California San Francisco
Vanqua Bio Inc
Walking Fish Therapeutics Inc
Yuhan Corp